Nadim Ajami
Executive Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Year:
2026
Year:
2026
Lower gastrointestinal graft-versus-host disease (LGI-GVHD) carries morbidity and mortality for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with critical contributions from the intestinal microbiome. In a retrospective cohort of metagenomic sequencing of allo-HSCT patient stool (n = 90), we found that a reduction in specific Parabacteroides and Bacteroides species around the time of engraftment contributes to LGI-GVHD risk. Given the known diverse carbohydrate degrading functionality of these bacteria, we investigated gene abundances for Carbohydrate-Active enZyme (CAZyme) and found that Parabacteroides merdae, Parabacteroides distasonis and Bacteroides ovatus abundances were significantly correlated with CAZymes in patients who did not develop LGI-GVHD compared to those who did. The specific gene abundances of xylosidase, which contribute to the degradation of xylose-containing polysaccharides, were significantly associated with reduced risk of LGI-GVHD. Together, these findings show the importance of carbohydrate degrading functionality of putative beneficial bacteria in mediating risk of LGI-GVHD.
Year:
2026
The gut microbiome has emerged as a key regulator of response to cancer immunotherapy. However, a better understanding of the underlying mechanisms by which the microbiome influences immunotherapy is needed to identify strategies to optimize outcomes. To this end, we developed a mathematical model to obtain insights into the effect of the microbiome on the immune system and immunotherapy response. This model was based on (i) gut microbiome data derived from preclinical studies, (ii) mathematical modeling of the antitumor immune response, (iii) association analysis of microbiome profiles with model-predicted immune profiles, and (iv) statistical models that correlate model parameters with the microbiome. The model was used to investigate the complexity of murine and human studies on microbiome modulation. Comparison of model predictions with experimental observations of tumor response in the training and test datasets supported the hypothesis that two model parameters, the activation and killing rate constants of immune cells, are the most influential in tumor progression and are potentially affected by microbiome composition. Evaluation of the associations between the gut microbiome and immune profile indicated that the components and structure of the gut microbiome affect the activation and killing rate of adaptive and innate immune cells. Overall, this study contributes to a deeper understanding of microbiome–cancer interactions and offers a framework for understanding how microbiome interactions influence cancer treatment outcomes. Significance: Integration of mathematical modeling and microbiome data reveals how gut microbiome components impact immune response, providing insights to optimize immunotherapy strategies. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.
Year:
2025
Background/Objectives: Immune checkpoint blockade (ICB) therapies have significantly improved outcomes in metastatic melanoma. However, immune-related adverse events (irAEs) and persistent chronic toxicities (CTs) among this emerging survivor population likely influence different facets of quality of life. This study characterized CT, patient-reported outcomes (PROs), diet, physical activity and gut microbiome features in a cohort of long-term survivors with a history of ICB-treated metastatic melanoma. Methods: Forty-eight patients with a history of metastatic melanoma who initiated ICB treatment at least 3 years earlier and were not currently on treatment were prospectively enrolled from a melanoma survivorship clinic. Participants completed screening questionnaires for depression, anxiety, diet and physical activity. The gut microbiome was characterized via metagenomic sequencing in a subsample (n = 39). Patients’ clinicopathological characteristics and experience of irAEs (during treatment) and CT (persisting >6 months after completion of therapy) were extracted retrospectively from the medical record. Results: In the overall cohort, 60% were experiencing CT, while 16% and 20% reported clinically relevant levels of depression and anxiety symptoms, respectively. We observed significant differences in overall gut microbiome composition between survivors with and without CT (p = 0.02). Consumption of fruit and vegetables was inversely associated with anxiety (ρ = 0.3, p = 0.038). Added sugar consumption was correlated with the severity of experienced symptoms (ρ = 0.4, p = 0.003), with pronounced associations across the spectrum of symptoms, including pain, fatigue and shortness of breath (p < 0.05). Conclusions: These results suggest that CT is experienced by a substantial proportion of ICB-treated metastatic melanoma survivors. Patients experiencing CT also showed distinct microbiome features. However, additional research in prospective settings is needed to confirm these hypotheses.
Year:
2025
Immune cell analysis by BMI and sex. A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis of the Gide cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor.
Year:
2025
Integrated gene set enrichment analysis of subgroups by body mass index BMI. This figure compares gene expression between overweight/obese (OW/OB) and normal (NL) BMI patients with metastatic melanoma across subgroups by sex, cohort, and tissue site. Supplementary Figure 2 presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients by subgroups. Red indicates upregulation in OW/OB verse NL.
Year:
2025
Integrated gene set enrichment analysis by body mass index (BMI) with correction for S phase. This figure presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients. Red indicates upregulation in OW/OB verse NL. The far left column is all patients, and then, an analysis controlling for sex, cohort, and tissue site is shown in the 3 columns to the right.
Year:
2025
Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 x IQR. The red dots represent OW/OB patients and the blue dots represent NL patients by BMI. This is a subgroup analysis of Figure 5C.
Year:
2025
Direct metabolite measurements from a subset of The Cancer Genome Atlas (TCGA) cohort. Comparison of additional tricarboxylic acid cycle metabolites measured by liquid chromatography/mass spectrometry between metastatic melanoma tumors from overweight/obese (OW/OB) patients by body mass index (BMI) verse normal (NL) BMI from The Cancer Genome Atlas (TCGA). Lines represent mean +/- SEM; each dot represents a single tumor.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (66)
Georgina V. Long
University of Sydney
Guido Kroemer
-
Lauren Haydu
Assistant Professor of Biostatistics
Mayo Clinic
Carrie Daniel
Professor
The University of Texas MD Anderson Cancer Center
Michael A. Davies
-
David J. Tweardy
The University of Texas MD Anderson Cancer Center
Richard Champlin
The University of Texas MD Anderson Cancer Center
Valerio Iebba
Assistant Professor
University of Trieste
Didier Hocquet
Full Prof. - Hospital Practitioner
Hôpital Jean Minjoz
olivier adotevi
INSERM UMR 1098 RIGHT
matthew ross
Assistant Professor
Baylor College of Medicine
Cheuk Hong Leung
The University of Texas MD Anderson Cancer Center
Mathieu Chevalier
Assistant Professor
INSERM U976, Institut de Recherche Saint-Louis, Université de Paris
Chantale Bernatchez
The University of Texas MD Anderson Cancer Center
Ralph J. DeBerardinis
University of Texas Southwestern Medical Center
Kristi Hoffman
Assistant Professor
Baylor College of Medicine
Markus Maeurer
University of Mainz
Jennifer L. McQuade
The University of Texas MD Anderson Cancer Center
Jun Li
Associate Professor
University of North Carolina at Chapel Hill
Alexander M. Menzies
University of Sydney
Julia Thorn-Seshold
Group Leader
Technische Universität Dresden
Xiaotao Zhang
Assistant Professor
Icahn School of Medicine at Mount Sinai
Theodore S. Nowicki
University of California
Greg M. Delgoffe
-
John Kirkwood
Distinguished Service Professor of Medicine
University of Pittsburgh
Simon Rothenfusser
Professor
Ludwig-Maximilians-Universität München
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
laurence ZITVOGEL
Université Paris-Saclay
Vashisht Yennu Nanda
Associate Professor
The University of Texas MD Anderson Cancer Center
Nicola Segata
Group Leader
University of Trento
Genevieve Boland
Chair of Surgery
Medical College of Wisconsin
Junya Fujimoto
Professor and Chair
Hiroshima University Hospital
John Thompson
Clinical Professor
University of Sydney
Triantafyllos Stylianopoulos
Associate Professor
-
Grant Fischer
Assistant Professor of Molecular Genetic Pathology (Tenure Track)
University of North Carolina at Chapel Hill
Alexandra Ikeguchi
Associate Professor
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Sebastian Kobold
University Hospital
I. Jolanda M. de Vries
Department head
Radboudumc
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Wen-Bin Tsai
Senior Staff Scientist
Baylor College of Medicine
Elizabeth Burton
The University of Texas MD Anderson Cancer Center
Michael White
Assistant Professor
-
Isabella C Glitza Oliva
Professor
The University of Texas MD Anderson Cancer Center
Aditya Mishra
University of Georgia
Lisa Derosa
Assistant Professor
Université Paris-Saclay
Ryan Sullivan
Harvard University
Christine Spencer
Parker Institute for Cancer Immunotherapy
Robert Jenq
Professor
City Of Hope National Medical Center
Dirk Schadendorf
University Hospital Essen
Han Liang
The University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam
Professor
The University of Texas MD Anderson Cancer Center
Silvia Formenti
Cornell University
James Wilmott
Associate Professor
The University of Sydney Library
Sophie Caillat-Zucman
Professeur
Université Paris Diderot
yana najjar
University of Pittsburgh
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Julie Densmore
Parker Institute for Cancer Immunotherapy
Christine Peterson
Associate Professor
Rice University
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Humam Kadara
The University of Texas MD Anderson Cancer Center
Richard A. Scolyer
Faculty Member
University of Sydney
Joseph Petrosino
Department Chair
Baylor College of Medicine
Nagireddy Putluri
Professor (Tenured)
Baylor College of Medicine
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
Weiyi Peng
Director
University of Houston
Make your next move.
Prepare your application
Review drafts before you send them.